Current Research

Current2022-05-18T15:42:18+02:00
606, 2024

First Berlin – M1 Kliniken AG Research Update (06.06.2024)

First Berlin Equity Research hat ein Research Update zu M1 Kliniken AG (ISIN: DE000A0STSQ8) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 18,00 auf EUR 28,00.Zusammenfas...

606, 2024

First Berlin – M1 Kliniken AG Research Update (06/06/2024)

First Berlin Equity Research has published a research update on M1 Kliniken AG (ISIN: DE000A0STSQ8). Analyst Ellis Acklin reiterated his BUY rating and increased the price target from EUR 18.00 to EUR 28.00.AbstractAudited 2023 reporting ...

306, 2024

First Berlin – H2APEX Group SCA Research Update (03/06/2024)

First Berlin Equity Research has published a research update on H2APEX Group SCA (ISIN: LU0472835155). Analyst Dr. Karsten von Blumenthal reiterated his BUY rating and maintained his EUR 9.00 price target.AbstractIn the first quarter, H2A...

3005, 2024

First Berlin – Aroundtown SA Research Update (30/05/2024)

First Berlin Equity Research has published a research update on Aroundtown SA (ISIN: LU1673108939). Analyst Ellis Acklin reiterated his BUY rating and increased the price target from EUR 3.40 to EUR 3.50.AbstractQ1 reporting again feature...

3005, 2024

First Berlin – Aroundtown SA Research Update (30.05.2024)

First Berlin Equity Research hat ein Research Update zu Aroundtown SA (ISIN: LU1673108939) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 3,40 auf EUR 3,50.Zusammenfassun...

2905, 2024

First Berlin – Enapter AG Research Update (29/05/2024)

First Berlin Equity Research has published a research update on Enapter AG (ISIN: DE000A255G02). Analyst Dr. Karsten von Blumenthal reiterated his BUY rating and decreased the price target from EUR 13.00 to EUR 11.00.AbstractEnapter is th...

2905, 2024

First Berlin – Enapter AG Research Update (29.05.2024)

First Berlin Equity Research hat ein Research Update zu Enapter AG (ISIN: DE000A255G02) veröffentlicht. Analyst Dr. Karsten von Blumenthal bestätigt seine BUY-Empfehlung und senkt das Kursziel von EUR 13,00 auf EUR 11,00.Zusamme...

Didn’t find what you’re looking for?

If you have unanswered questions about our services and are classified as an institutional investor, contact us to see how we can service your institution.

Nach oben